Application of targeting ZNF468 / PRMT1 / VEGF-C signaling axis in early diagnosis and treatment of lymph node metastasis in esophageal cancer
By targeting the ZNF468/PRMT1/VEGF-C signaling axis, diagnostic kits and inhibitory reagents were developed to solve the problems of lymphangiogenesis and lymph node metastasis in esophageal cancer, and significantly improved the prognosis of patients with esophageal squamous cell carcinoma.
Patent Information
- Application Number
- CN202410183397.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-02-19
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-02-19
AI Technical Summary
Diagnosis of esophageal cancer usually occurs in the advanced stage, and lymphangiogenesis and lymph node metastasis lead to adverse prognosis. The prior art is difficult to effectively inhibit tumor-related lymphangiogenesis and lymph node metastasis, and new targets are needed to improve the prognosis.
Diagnostic kits were developed to detect ZNF468, VEGF-C and PRMT1 expression levels by targeting the ZNF468/PRMT1/VEGF-C signaling axis, and used reagents that inhibit ZNF468, PRMT1 and VEGF-C to inhibit lymphangiogenesis and lymph node metastasis, including Chemical drug AMI-1 was constructed to verify the efficacy of mouse models.
It significantly inhibited lymphangiogenesis and lymph node metastasis of ZNF468 overexpressed esophageal squamous cell carcinoma, providing new therapeutic strategies and diagnostic methods, and improving the prognosis of patients with esophageal squamous cell carcinoma.
Smart Images

Figure CN118006779B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and specifically to an application of targeting ZNF468 / PRMT1 / VEGF-C signal axis in the treatment and early diagnosis of esophageal cancer lymph node metastasis. Background Art
[0002] Esophageal cancer is a major global health challenge and is the sixth leading cause of cancer-related deaths worldwide in 2020, with a 5-year survival rate of less than 20%. Esophageal squamous cell carcinoma (ESCC) is the leading cause of cancer death, accounting for approximately 90% of esophageal cancer cases.
[0003] The diagnosis of esophageal cancer often occurs in the late stage, and the main treatment for esophageal cancer is esophagectomy, however, the overall prognosis is still poor.
[0004] Studies have shown that ESCC patients develop lymphangiogenesis in the early stage, which leads to lymph node metastasis. The poor prognosis of ESCC is related to lymphangiogenesis and lymph node metastasis. Therefore, it is urgent to understand the molecular mechanism and identification of ESCC lymphangiogenesis and lymph node metastasis, and to identify a new therapeutic target to improve the prognosis of ESCC.
[0005] The vascular endothelial growth factor family (VEGF, such as VEGFA, VEGFB, VEGF-C, VEGFD) and placental growth factor (PLGF) are involved in lymphangiogenesis, among which VEGF-C (vascular endothelial growth factor C) is a stimulator of lymphatic endothelial cells, and VEGF-C and VEGFR3 play a major role in lymphangiogenesis.
[0006] In addition, lymph node metastasis, poor prognosis, lymphatic invasion, and distant metastasis were associated with increased VEGF-C expression in tumors, and the expression level of VEGF-C was associated with a lower 5-year survival rate in ESCC.
[0007] However, selective inhibitors targeting the VEGF-C receptor VEGFR3 are currently under preclinical investigation, such as EVT801 and SAR131675, so identifying new therapeutic targets to inhibit tumor-associated lymphangiogenesis and lymph node metastasis may be a more effective strategy for clinical intervention in cancer.
[0008] ZNF468 is a member of the zinc finger protein family, the world's largest family of transcription factors with finger domains, and plays an important role in multiple biological processes. However, there is still little information about the role of ZNF468 in ESCC. Recent studies have identified multiple zinc finger proteins as key regulators of cancer initiation and progression.
[0009] For example, Zhang et al. reported that the potential tumor suppressor ZNF671 was downregulated in NPC and promoted cell proliferation and tumorigenicity.
[0010] An and colleagues found that ectopic expression of ZNF575 can inhibit colorectal cancer cell proliferation, promote cell apoptosis, and inhibit tumor growth.
[0011] In addition, Hu and colleagues confirmed that ZNF668 can inhibit cancer development through the p53 pathway and identified it as a potential tumor suppressor in breast cancer. He and colleagues found that ZNF154 acts as a tumor suppressor in ESCC and is associated with poor prognosis.
[0012] We speculate that ZNF468 may also play a key role in the tumorigenesis and progression of ESCC. Therefore, exploring the potential of ZNF468 as a therapeutic target for ESCC may help us develop new therapeutic strategies and improve the prognosis of ESCC patients. Summary of the invention
[0013] The purpose of the present invention is to address the problems existing in the prior art and provide an application of targeting the ZNF468 / PRMT1 / VEGF-C signaling axis in the treatment and early diagnosis of esophageal cancer lymph node metastasis.
[0014] To achieve the above-mentioned purpose, the present invention provides the following technical solutions:
[0015] The application of ZNF468 as a target in the preparation of products for tumor treatment, tumor prognosis, and prediction of tumor treatment effects.
[0016] Preferably, the product for tumor treatment, tumor prognosis, or / and prediction of tumor treatment effect comprises a diagnostic kit.
[0017] Preferably, the diagnostic kit contains at least one of a reagent for detecting the expression level of ZNF468, a reagent for detecting the expression level of VEGF-C, and a reagent for detecting the expression level of PRMT1.
[0018] Preferably, the reagent for detecting ZNF468 comprises at least one of a reagent for detecting whether the ZNF468 gene is overexpressed, a reagent for quantitatively detecting the RNA transcription level of ZNF468, and a reagent for quantitatively detecting the protein expression level of ZNF468.
[0019] The invention discloses an application of a reagent for inhibiting the expression of ZNF468 protein in preparing a drug for inhibiting lymphangiogenesis and improving the therapeutic effect of tumors.
[0020] A reagent for inhibiting PRMT1 expression and a reagent for inhibiting VEGF-C expression are used in the preparation of a drug for treating ZNF468 overexpressed tumors and / or in the preparation of a drug for improving the immunotherapy effect of ZNF468 overexpressed tumors.
[0021] Preferably, the agent that inhibits PRMT1 expression includes the chemical drug AMI-1.
[0022] A drug for improving the therapeutic efficacy of tumors and prognosis, wherein the drug for improving the therapeutic efficacy of tumors and prognosis contains at least one of a reagent for inhibiting the expression of ZNF468, a reagent for inhibiting the expression of VEGF-C, and a reagent for inhibiting the expression of PRMT1.
[0023] A pharmaceutical agent for inhibiting the therapeutic efficacy of ZNF468 overexpressing tumors.
[0024] Preferably, the agent for inhibiting the therapeutic effect of ZNF468 overexpressing tumors contains at least one of an agent for inhibiting the expression of ZNF468, an agent for inhibiting the expression of VEGF-C, and an agent for inhibiting the expression of PRMT1.
[0025] Beneficial effects of the present invention:
[0026] 1) The present invention found that when ZNF468 is overexpressed, the body significantly promotes the lymphangiogenesis and lymph node metastasis of tumors (such as esophageal squamous cell carcinoma) by recruiting and binding to PRMT1 to enhance the transcriptional activity of VEGF-C. The present invention combined the use of agents that inhibit PRMT1 expression to significantly inhibit the lymphangiogenesis mechanism of esophageal squamous cell carcinoma with ZNF468 overexpression. These results show that ZNF468 plays an important role in lymphangiogenesis and lymph node metastasis in patients with esophageal squamous cell carcinoma, and can be used as a new treatment strategy for ZNF468 overexpressing tumors;
[0027] 2) The present invention discovered the application of ZNF468 gene in lymphangiogenesis and lymph node metastasis in esophageal squamous cell carcinoma. The present invention successfully constructed esophageal squamous cell carcinoma cell models that overexpressed ZNF468 and interfered with ZNF468 expression, successfully established a mouse esophageal squamous cell carcinoma footpad lymph node metastasis model, and found through immunohistochemistry, cell tubule formation and other experimental analyses that inhibition of ZNF468 can reduce lymphangiogenesis and lymph node metastasis in vivo and in vitro, thereby inhibiting tumor growth. The present invention used TCGA database analysis to find that up-regulation of ZNF468 protein expression is closely related to the metastasis survival rate of patients with esophageal squamous cell carcinoma.
[0028] 3) At the mechanism level, the present invention reveals that ZNF468 binds to the VEGF-C promoter and increases the transcriptional activity of VEGF-C through CHIP-PCR, luciferase reporter gene experiments, etc.; through mass spectrometry experiments, immunoprecipitation technology and ChIP experiments, it is found that ZNF468 increases the expression of VEGF-C in esophageal squamous cell carcinoma and promotes lymphangiogenesis and lymph node metastasis; the specific binding region of ZNF468 and the downstream gene VEGF-C promoter is analyzed, providing a new molecular regulatory mechanism for the oncogene ZNF468 to regulate target genes; finally, the present invention uses tumor tissue samples, conducts immunohistochemistry experiments and analyzes, and finds that the combined use of PRMT1 inhibitors greatly reduces the expression of VEGF-C protein in tumors. This suggests that the ZNF468 gene can be used as an important target molecule to promote lymphangiogenesis and lymph node metastasis in patients with esophageal squamous cell carcinoma. In summary, this study found that ZNF468 is an important promoter of the development of esophageal squamous cell carcinoma and is of great significance in the development of cancer. This will provide a new treatment direction for clinical tumor treatment. The present invention provides a new diagnosis and treatment method and drug screening platform for tumor diseases.
[0029] The features and advantages of the present invention will be described in detail in the following detailed description. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] FIG1 (A) is an immunohistochemical staining analysis of the expression of ZNF468 in ESCC tissues with lymph node metastasis (LN+) or without lymph node metastasis (LN-);
[0031] Figure 1 (B) is an immunohistochemical staining analysis of the expression of ZNF468 and Lyve-1 in ESCC tissues;
[0032] Figure 1 (C) shows the Kaplan-Meier survival curve;
[0033] Figure 1 (D) is the mRNA expression of ZNF468 in ESCC tissues with or without lymph node metastasis in the TCGA dataset;
[0034] Figure 1(E) is a survival prognosis analysis diagram in the TCGA dataset;
[0035] Figure 2 (A) is a diagram of the mouse footpad lymph node metastasis model;
[0036] Figure 2 (B) shows the lymph node images (left) and lymph node volume quantification images (right) of each experimental group;
[0037] Figure 2 (C) is the expression of Lyve-1 in each group detected by IHC;
[0038] Figure 2 (D) shows the expression of ZNF468 in each group detected by IHC (left) and the lymph node metastasis rate of the cells shown (right);
[0039] FIG3 (A) is a diagram showing the tube formation ability of HLECs cells verified by a tube formation experiment;
[0040] FIG3(B) is a diagram showing the results of a cell perforation experiment;
[0041] FIG4 (A) is a diagram showing the predicted binding sites of ZNF468 using the JASPAR database;
[0042] FIG4 (B) is a graph showing the results of ChIP-PCR using IgG or ZNF468 antibody to detect two types of ESCC cells;
[0043] FIG4(C) is a graph showing relative luciferase activity in cells;
[0044] FIG4(D) is a diagram showing a specific site where ZNF468 may be located in the VEGF-C promoter by ChIP-PCR analysis;
[0045] FIG5 (A) is a schematic diagram of searching for key factors regulating VEGF-C (left) and a diagram of the interaction between endogenous ZNF468 and endogenous PRMT1 in ESCC cells (right);
[0046] Figure 5(B) is a Western blot;
[0047] Figure 5 (C) shows the enrichment of H4R3me2a in the VEGF-C promoter region;
[0048] FIG5(D) is a graph showing the effect of PRMT1 on the luciferase activity of the VEGF-C promoter;
[0049] FIG5(E) is a graph showing the effect of PRMT1 on VEGF-C protein levels in ESCC cells;
[0050] Figure 6 (A) is a graph showing the expression of ZNF468 in each group as detected by IHC and the lymph node metastasis rate of cells;
[0051] Figure 6 (B) is a diagram showing the expression of Lyve-1 in each group detected by IHC;
[0052] Figure 7 Genetic maps for various cancers. DETAILED DESCRIPTION
[0053] In order to make the purpose, technical scheme and beneficial effects of the present invention clearer, the present invention is further described in detail below in conjunction with the accompanying drawings and specific embodiments. Examples of the embodiments are shown in the accompanying drawings. It should be understood that the specific embodiments described in the following embodiments of the present invention are only exemplary descriptions of the specific embodiments of the present invention, and are intended to be used to explain the present invention, but do not constitute a limitation of the present invention.
[0054] The endpoints of the scope disclosed in this article and any value are not limited to this accurate scope or value, and these scopes or values should be understood as comprising values close to these scopes or values.For numerical range, between the endpoint values of each scope, between the endpoint values of each scope and a separate point value, and between separate point values, one or more new numerical ranges can be combined with each other, and these numerical ranges should be considered as specifically disclosed in this article.In the description of the application, unless otherwise stated, the meaning of similar words such as "one / a kind", "multiple / multiple" is two / kinds or more than two / kinds.
[0055] Example 1
[0056] Upregulation of ZNF468 is associated with lymphatic metastasis and lymphangiogenesis.
[0057] Methods: The relationship between the expression of ZNF468 in tumor tissues and normal tissues and lymphatic metastasis and lymphangiogenesis was evaluated by immunohistochemistry (IHC) results of clinical samples and the TCGA database. The results are shown in Figure 1(A) to (E).
[0058] Results: As shown in Figure 1(A) to (E), IHC results showed that the expression level of ZNF468 was significantly increased in tumor tissues. Figure 1(C) compared ESCC patients with higher or lower expression levels of ZNF468 and Lyve-1; at the same time, the ability of lymph node metastasis and lymphangiogenesis was significantly improved. TCGA database analysis showed that when ZNF468 was lowly expressed, the metastasis-free survival time was longer.
[0059] Conclusion: ZNF468 is highly expressed in tumor tissues, and the expression level of ZNF468 is correlated with lymphatic metastasis and lymphangiogenesis.
[0060] Example 2
[0061] High expression of ZNF468 can promote lymph node metastasis and lymphangiogenesis in vivo.
[0062] Methods: A mouse footpad experimental model was established. A certain amount of esophageal cancer (Eca109) tumor cells were injected into the footpads of C57 mice, including the Eca109-vector group, the Eca109-ZNF468 group, the Eca109-Control group, and the Eca109-shRNA group. The tumors were further analyzed by immunohistochemistry (IHC) staining. The results are shown in Figure 2(A) to (D).
[0063] Results: Analysis of inguinal lymph nodes in the mouse footpad model revealed that (Figure 2(A)), the lymph node volume of the Eca109-ZNF468 group with ZNF468 overexpression was larger than that of other groups, while the inguinal lymph node volume of the Eca109 group with ZNF468 silencing was significantly reduced. IHC staining results showed that the ability of lymphangiogenesis and lymph node metastasis in the Eca109-ZNF468 group was significantly enhanced.
[0064] Conclusion: ZNF468 can promote lymph node metastasis and lymphangiogenesis in mice in vivo.
[0065] Example 3
[0066] Expression of ZNF468 can induce lymphangiogenesis and migration ability of esophageal cancer cells in vitro.
[0067] Methods: Eca109 and KYSE30 cells were selected and transfected with vector, ZNF468, control, ZNF468-RNA#1, and ZNF468-RNA#2 plasmids, respectively. Tubule formation assay and cell migration assay were performed using the transfected cells. The results are shown in Figures 3(A) and 3(B).
[0068] Results: In the experimental group with high expression of ZNF468 in esophageal cancer cells, the tube formation and migration ability of lymphatic endothelial cells were significantly enhanced, while the opposite result occurred when ZNF468 was inhibited.
[0069] Conclusion: The expression of ZNF468 promotes lymphangiogenesis and migration of esophageal cancer cells in vitro.
[0070] Example 4
[0071] ZNF468 binds to the VEGF-C promoter and regulates the transcriptional activity of VEGF-C.
[0072] Methods: We first used the JASPAR database to predict potential ZNF468 binding sites in the VEGF-C promoter, and then used chromatin immunoprecipitation (CHIP) and luciferase reporter gene assays to verify the relationship between ZNF468 and VEGF-C. CHIP was used to analyze the association of ZNF468 in the VEGF-C promoter region. The results are shown in Figure 4(A) to (D).
[0073] Results: The JASPAR database predicted three potential ZNF468 binding sites in the VEGF-C promoter. ChIP assay showed that ZNF468 was significantly associated with the VEGF-C promoter in esophageal cancer. Luciferase reporter gene assay showed that in esophageal cancer, ZNF468 overexpression promoted the luciferase activity of the VEGF-C promoter, while silencing ZNF468 inhibited the luciferase activity of the promoter. In addition, chromatin immunoprecipitation assay showed that ZNF468 bound to the F5 region of the VEGF-C promoter region.
[0074] Conclusion: ZNF468 upregulates VEGF-C expression in esophageal cancer by targeting VEGF-C promoter transcription.
[0075] Example 5
[0076] The mechanism by which ZNF468 participates in VEGF-C-promoted lymphangiogenesis is achieved through interaction with PRMT1.
[0077] Methods: The mechanism of ZNF468 transcriptional activation of VEGF-C in esophageal cancer was explored by biotinylated inactivated Cas9 (dCas9) capture analysis combined with immunoprecipitation Co-IP and mass spectrometry analysis. In addition, PRMT1 activity was inhibited using PRMT1 inhibitor (AMI-1) and siPRMT1 was used to treat esophageal cancer cells. The results are shown in Figure 5 (A) to (E).
[0078] Results: IP / MS assays showed that ZNF468 and PRMT1 were involved in the transcriptional regulation of VEGF-C in esophageal cancer cells. Co-immunoprecipitation (co-IP) and Western blot analysis showed that ZNF468 interacted with PRMT1 in esophageal cancer cells. Silencing ZNF468 or PRMT1 significantly reduced the level of H4R3me2a on the VEGF-C promoter, and the expression level of VEGF-C was significantly decreased after treatment of esophageal cancer cells with the PRMT1 inhibitor AMI-1 and with siPRMT1.
[0079] Conclusion: PRMT1 is involved in the transcriptional activation of VEGF-C induced by ZNF468 and upregulates the transcriptional level of VEGF-C through methylation modification of H4R3. This indicates that the mechanism of ZNF468 participating in VEGF-C-promoted lymphangiogenesis is achieved through interaction with PRMT1.
[0080] Embodiment 6:
[0081] Effects of AMI-1 and VEGF-C-RNAi on lymph node metastasis and lymphangiogenesis in ZNF468-overexpressing esophageal cancer cells.
[0082] Methods: A mouse footpad model was established, and Eca109 with high expression of ZNF468 was injected. The mice were treated with PRMT1 inhibitor AMI-1 and VEGF-C-RNAi, and a control group Vehicle was set up. The tumors of the mice were subsequently taken for immunohistochemistry (IHC) staining and analyzed. The results are shown in Figure 6 (A) and Figure 6 (B).
[0083] Results: In vivo experiments showed that the proportion of lymph node metastasis in AIM-1-treated mice and VEGF-C-RNAi-treated mice was significantly reduced compared with that in the control group, with the AMI-1-treated group showing the best effect. Similarly, tumor tissues of AIM-1- and VEGF-C-RNAi-treated mice showed a significant reduction in Lyve-1 lymphatic vessels compared with tumor tissues of the control group.
[0084] Conclusion: The data showed that PRMT1 was involved in the ZNF468-induced VEGF-C transcription process, and verified that the lymphangiogenesis and lymph node metastasis of ZNF468-overexpressing esophageal cancer were significantly inhibited after treatment with the PRMT1 inhibitor AMI-1 and VEGF-C-RNAi, proving that ZNF468 and PRMT1 are jointly involved in regulating the role of VEGF-C.
[0085] Example 7
[0086] Clinical significance of ZNF468 and VEGF-C expression in various cancers.
[0087] Methods: GSE and TCGA clinical databases were analyzed. Figure 7 shown.
[0088] Results: Combined with clinical information, it was demonstrated that the expression of ZNF468 was positively correlated with the expression of VEGF-C in many cancers, revealing the universality of ZNF468 as a tumor biomarker in various tumors.
[0089] Conclusion: The expression of ZNF468 and VEGF-C is associated with a variety of digestive cancers, demonstrating that the expression of ZNF468 is positively correlated with the expression of VEGF-C in many cancers, revealing the universality of ZNF468 as a tumor biomarker in a variety of tumors.
[0090] It should be noted that the specific parameters or some reagents in the above embodiments are specific embodiments or preferred embodiments of the present invention, rather than limiting the present invention; those skilled in the art can make adaptive adjustments within the scope of the present invention.
Claims
1. Application of a reagent for detecting ZNF468 in the preparation of a diagnostic kit for esophageal cancer lymph node metastasis and lymphangiogenesis, characterized in that: The reagent for detecting ZNF468 is at least one of a reagent for detecting whether the ZNF468 gene is overexpressed and a reagent for quantitatively detecting the RNA transcription level of ZNF468.
Citation Information
Patent Citations
Application of PRMT1 (protein arginine N-methyltransferase 1) inhibitor to preparation of drug for treating cocaine addiction
CN105125571A
Application of VEGF-C in screening of medicine for diagnosing or treating implantation metastasis cancer
CN106421788A
Combination therapy
CN110214010A
Application of reagent for detecting expression level of zinc finger protein 468 and kit
CN110273000A
Method for predicting the occurrence of metastasis in breast cancer patients
US20100113297A1
